PDE4A and psoriasis: Apremilast 3 (Figure 2) is an oral PDE4 inhibitor with IC50 = 74 nM, which was approved by FDA in 2014 and mainly used for the treatment of psoriasis and other chronic immune-mediated diseases [46].